Moleculin Biotech Inc MBRX

Morningstar Rating
$7.87 −0.19 (2.36%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

MBRX is trading at a LOCK|?!YCK premium.
Price
$7.87
Fair Value
LOCK|.&mX<R>
Uncertainty
LOCK|!S >#!$l
1-Star Price
LOCK|.#$D@!&
5-Star Price
LOCK|#F&hQ$
Economic Moat
LOCK|>B
Capital Allocation
—

News

Trading Information

Previous Close Price
$8.06
Day Range
$7.71–8.10
52-Week Range
$3.23–229.40
Bid/Ask
$6.35 / $10.00
Shares Outstanding
1.02M
Market Cap
$8.02M
Volume/Avg
9,901 / 44,683

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

Moleculin Biotech Inc is a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name naxtarubicin. The company has two additional portfolios of technologies for hard-to-treat cancers and viruses with clinical and preclinical research funded by investigators at academic institutions. The Company operates in one reportable segment, which is the development and commercialization of drug products.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
17

Valuation

Metric
MBRX
Price/Earnings (Normalized)
—
Price/Book Value
0.24
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
MBRX
Quick Ratio
0.78
Current Ratio
0.94
Interest Coverage
—
Quick Ratio
MBRX

Profitability

Metric
MBRX
Return on Assets (Normalized)
−294.41%
Return on Equity (Normalized)
−4,154.14%
Return on Invested Capital (Normalized)
−3,371.18%
Return on Assets
MBRX

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|mcm<V<#LOCK|Q%PX#$137B
Regeneron Pharmaceuticals Inc
REGN
LOCK|b>Y^YpCLOCK|m%CD$99B
Moderna Inc
MRNA
LOCK|#zD&rwLOCK|xk>$90B
argenx SE ADR
ARGX
LOCK|?nD^w?&LOCK|^p#$61B
BeOne Medicines Ltd ADR
ONC
LOCK|v%Ty>%LOCK|j<G$48B
Royalty Pharma PLC Class A
RPRX
LOCK|#df?rl&!LOCK|K#gBY$31B
Incyte Corp
INCY
LOCK|qC!WWm<LOCK|^!$25B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|&!J$xfVLOCK|Dw>!%$22B
BioNTech SE ADR
BNTX
LOCK|fQm%d<@LOCK|Jr&$21B
Jazz Pharmaceuticals PLC
JAZZ
LOCK|Cqt@^hLOCK|wfG$16B

Sponsor Center